← Back to Search

Chemotherapy

NanoKnife IRE for Pancreatic Cancer (DIRECT Trial)

Phase 3
Waitlist Available
Research Sponsored by Angiodynamics, Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up time (in months) from randomization to the date of death for any reason, assessed through at least 24 months.
Awards & highlights
No Placebo-Only Group
Pivotal Trial

Summary

This trial compares chemotherapy alone to chemotherapy plus an electrical pulse treatment in patients who have responded well to initial chemotherapy. The goal is to see if adding the electrical pulse treatment can better destroy cancer cells. Electrochemotherapy is a method that uses electric pulses to increase the uptake and effectiveness of chemotherapeutic drugs in cancer cells.

Eligible Conditions
  • Pancreatic Cancer

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~time (in months) from randomization to the date of death for any reason, assessed through at least 24 months.
This trial's timeline: 3 weeks for screening, Varies for treatment, and time (in months) from randomization to the date of death for any reason, assessed through at least 24 months. for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Overall Survival

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.
Pivotal Trial
The final step before approval, pivotal trials feature drugs that have already shown basic safety & efficacy.

Trial Design

2Treatment groups
Experimental Treatment
Active Control
Group I: IREExperimental Treatment2 Interventions
Group II: ControlActive Control1 Intervention
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
NanoKnife System
2017
N/A
~20

Find a Location

Who is running the clinical trial?

Angiodynamics, Inc.Lead Sponsor
25 Previous Clinical Trials
2,325 Total Patients Enrolled

Media Library

Modified FOLFIRINOX Regimen (Chemotherapy) Clinical Trial Eligibility Overview. Trial Name: NCT03899636 — Phase 3
Pancreatic Cancer Research Study Groups: Control, IRE
Pancreatic Cancer Clinical Trial 2023: Modified FOLFIRINOX Regimen Highlights & Side Effects. Trial Name: NCT03899636 — Phase 3
Modified FOLFIRINOX Regimen (Chemotherapy) 2023 Treatment Timeline for Medical Study. Trial Name: NCT03899636 — Phase 3
~111 spots leftby Dec 2025